These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37507070)

  • 21. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
    Bachert C; Sousa AR; Han JK; Schlosser RJ; Sowerby LJ; Hopkins C; Maspero JF; Smith SG; Kante O; Karidi-Andrioti DE; Mayer B; Chan RH; Yancey SW; Chaker AM
    J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
    Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IL5 therapies for asthma.
    Farne HA; Wilson A; Powell C; Bax L; Milan SJ
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Lemiere C; Taillé C; Lee JK; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Liu MC
    Respir Res; 2021 Jun; 22(1):184. PubMed ID: 34158028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
    Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
    Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
    Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
    Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
    J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of gastroesophageal reflux disease in patients with asthma and chronic obstructive pulmonary disease.
    Bor S; Kitapcioglu G; Solak ZA; Ertilav M; Erdinc M
    J Gastroenterol Hepatol; 2010 Feb; 25(2):309-13. PubMed ID: 19817951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic.
    Langton D; Sha J; Guo S; Sharp J; Banks C; Wang W; Plummer V; Thien F
    Respirology; 2020 Dec; 25(12):1243-1249. PubMed ID: 32365431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA.
    Mullol J; Fokkens WJ; Smith SG; Keeley T; Zhang L; Howarth P; Chan RH; Bachert C
    Rhinology; 2024 Dec; 62(6):669-680. PubMed ID: 39323188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.
    Terashima T; Shinozaki T; Iwami E; Nakajima T; Matsuzaki T
    BMC Pulm Med; 2018 Mar; 18(1):53. PubMed ID: 29587693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD.
    Baumeler L; Papakonstantinou E; Milenkovic B; Lacoma A; Louis R; Aerts JG; Welte T; Kostikas K; Blasi F; Boersma W; Torres A; Rohde GG; Boeck L; Rakic J; Scherr A; Tamm M; Stolz D
    Respirology; 2016 Jul; 21(5):883-90. PubMed ID: 26970108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
    Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.
    Heffler E; Saccheri F; Bartezaghi M; Canonica GW
    Clin Transl Allergy; 2020; 10():25. PubMed ID: 32607141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.
    Pavord I; Gardiner F; Heaney LG; Domingo C; Price RG; Pullan A; Oppenheimer J; Brusselle G; Nagase H; Chupp G; Pizzichini E; Bañas-Conejero D; Howarth P
    Front Immunol; 2023; 14():1150162. PubMed ID: 37122713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.